Cycad Group

Prelude is a technology company headquartered in Manchester, New Hampshire, specializing in enhancing cybersecurity for organizations. Founded in 2018, Prelude focuses on providing visibility into security systems through a suite of products that enable continuous probing. This approach allows organizations to proactively assess their security posture by translating complex security concepts into straightforward queries, facilitating comprehensive understanding and management of vulnerabilities. By offering internal intelligence, Prelude helps clients identify, prioritize, and address security issues effectively, thereby strengthening their defenses against emerging threats.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments, specifically minibodies, to provide diagnostic imaging solutions and insights into cancer immunotherapy. Its product line includes advanced imaging agents such as the CD8 ImmunoPET™ and PSMA PET, which target specific molecular markers in various cancers, including prostate and immune-oncology. These imaging agents are designed to enhance patient selection and monitor treatment progress, facilitating precision medicine. Currently, ImaginAb's lead candidate, 89Zr crefmirlimab berdoxam, is undergoing Phase II clinical trials and has been licensed by multiple pharmaceutical and biotech companies for use in their immunotherapy clinical trials.

Lixivia, Inc. is a Santa Barbara, California-based company founded in 2012 that specializes in the purification and separation of minerals. It develops cost-effective and scalable processes aimed at enhancing the value of various mineral mixtures, including low-grade lime, dolime, steel and iron slag, rare earth metals, and lithium. Lixivia's innovative techniques effectively stabilize steel slag for civil engineering applications while producing high-purity calcium minerals. By carefully selecting chemical methodologies and process conditions, the company addresses industry challenges, enabling clients to maximize the value extracted from their mineral resources.

Formetrix Metals designs patented steel alloys for 3D printed components.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments, specifically minibodies, to provide diagnostic imaging solutions and insights into cancer immunotherapy. Its product line includes advanced imaging agents such as the CD8 ImmunoPET™ and PSMA PET, which target specific molecular markers in various cancers, including prostate and immune-oncology. These imaging agents are designed to enhance patient selection and monitor treatment progress, facilitating precision medicine. Currently, ImaginAb's lead candidate, 89Zr crefmirlimab berdoxam, is undergoing Phase II clinical trials and has been licensed by multiple pharmaceutical and biotech companies for use in their immunotherapy clinical trials.

NanoSteel is an advanced materials company focused on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. It specializes in proprietary alloys intended for automotive lightweight applications, developing multiple generations of ferrous materials innovations, including metallic coatings and additive manufacturing powders. With over 300 patents filed and granted globally, NanoSteel's nanostructured steel designs deliver next-generation performance across various industrial sectors, including oil and gas, mining, cement, concrete, and power. Its advanced high strength steel (AHSS) sheet material is particularly significant, as it aims to transform steel usage in the automotive industry by enabling manufacturers to produce new, lightweight vehicles that comply with stringent fuel economy regulations while avoiding costly production processes.

Agile RF Systems is a company that focuses on the design and development of advanced wireless systems for various applications, including sensors and communications. It specializes in creating small, tactical radars tailored for weather monitoring and counter unmanned aerial systems (UAS), as well as satellite communications. The company also produces active electronically steered antennas and millimeter-wave antennas, allowing for enhanced communication capabilities. By integrating active electronically steered antennas with multi-channel software-defined radios, Agile RF Systems aims to provide innovative solutions that meet the evolving demands of the wireless technology market.

ClarVista Medical, Inc. is a California-based company focused on developing innovative products to address challenging ophthalmic conditions. Founded in 2012, it specializes in the HARMONI modular intraocular lens system, which enhances vision optimization during cataract surgery. The company emerged from Prospex Medical, a medical device incubator, and has since developed a robust portfolio of intellectual property. ClarVista Medical has successfully completed the first generation of the HARMONI system and conducted initial human clinical studies. It is currently working on the second generation of the HARMONI system, aiming to conduct larger clinical trials and secure essential regulatory approvals. The company's technology allows for the initial positioning of the lens and facilitates easy exchange of the lens optic, thereby providing healthcare practitioners with a customizable solution for cataract surgery tailored to individual patient needs.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based therapies for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra creates novel biological medicines targeting a range of conditions. Its product pipeline includes VIS410, a monoclonal antibody aimed at all known strains of influenza A, VIS513 for Dengue treatment, VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649 for Immunoglobulin A Nephropathy. Founded in 2007 and originally named Parasol Therapeutics, Inc., the company rebranded to Visterra in April 2010 and is headquartered in Waltham, Massachusetts. As of August 2018, Visterra operates as a subsidiary of Otsuka America, Inc.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments, specifically minibodies, to provide diagnostic imaging solutions and insights into cancer immunotherapy. Its product line includes advanced imaging agents such as the CD8 ImmunoPET™ and PSMA PET, which target specific molecular markers in various cancers, including prostate and immune-oncology. These imaging agents are designed to enhance patient selection and monitor treatment progress, facilitating precision medicine. Currently, ImaginAb's lead candidate, 89Zr crefmirlimab berdoxam, is undergoing Phase II clinical trials and has been licensed by multiple pharmaceutical and biotech companies for use in their immunotherapy clinical trials.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

OvaScience, Inc. is a fertility company focused on discovering and commercializing innovative treatment options for women experiencing infertility. Founded in 2011 and headquartered in Waltham, Massachusetts, OvaScience developed proprietary technology based on the identification of egg precursor (EggPC) cells, enabling new approaches to fertility treatments. Its key offerings include OvaPrime, which aims to restore a woman's natural egg production by utilizing her own EggPC cells; OvaTure, which matures these cells into fertilizable eggs outside the body without hormone stimulation; and AUGMENT, which enhances fertilization and pregnancy rates using mitochondria from the woman’s EggPC cells. The company’s technology is exclusively licensed from Harvard Medical School and Massachusetts General Hospital, and it has been supported by a team of experts in reproductive science and embryology. OvaScience was initially known as Ovastem, Inc. before rebranding in 2011. In December 2018, OvaScience was acquired by Millendo Therapeutics, marking a significant shift in its operational focus.

ImaginAb, Inc. is a clinical stage biotechnology company specializing in immune oncology imaging and radiopharmaceutical therapy. Founded in 2007 and based in Inglewood, California, the company develops engineered antibody fragments, specifically minibodies, to provide diagnostic imaging solutions and insights into cancer immunotherapy. Its product line includes advanced imaging agents such as the CD8 ImmunoPET™ and PSMA PET, which target specific molecular markers in various cancers, including prostate and immune-oncology. These imaging agents are designed to enhance patient selection and monitor treatment progress, facilitating precision medicine. Currently, ImaginAb's lead candidate, 89Zr crefmirlimab berdoxam, is undergoing Phase II clinical trials and has been licensed by multiple pharmaceutical and biotech companies for use in their immunotherapy clinical trials.

Iosil Energy Corporation, founded in 2007 and based in Groveport, Ohio, specializes in the production and marketing of high-purity solar grade polysilicon, a crucial raw material for solar cells. The company efficiently leverages waste materials, specifically the byproducts generated from wafer sawing operations, to manufacture its polysilicon. This innovative approach not only reduces costs but also minimizes energy consumption and equipment requirements during production. In addition to its manufacturing capabilities, Iosil Energy's research and development facilities, located at the National Institute for Nanotechnology in Edmonton, Alberta, focus on improving purification technologies for silicon, contributing to the advancement of sustainable energy solutions.

NanoSteel is an advanced materials company focused on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. It specializes in proprietary alloys intended for automotive lightweight applications, developing multiple generations of ferrous materials innovations, including metallic coatings and additive manufacturing powders. With over 300 patents filed and granted globally, NanoSteel's nanostructured steel designs deliver next-generation performance across various industrial sectors, including oil and gas, mining, cement, concrete, and power. Its advanced high strength steel (AHSS) sheet material is particularly significant, as it aims to transform steel usage in the automotive industry by enabling manufacturers to produce new, lightweight vehicles that comply with stringent fuel economy regulations while avoiding costly production processes.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

SOFIE is a company focused on advancing theranostics through the development of molecular imaging probes and devices. By simplifying the traditionally complex and costly aspects of theranostic technology, SOFIE aims to enhance the adoption and application of its products. The company offers a comprehensive range of imaging and radiochemistry systems, supported by a robust radiopharmacy network and contract manufacturing capabilities. These resources facilitate the supply of novel agents for both diagnosis and therapy, thereby improving patient health outcomes. Furthermore, SOFIE's devices assist physicians in identifying tumors that are responsive to targeted drugs, enabling personalized healthcare solutions and tailored treatment options for patients.

Solaria Corporation is a solar technology company that specializes in designing, developing, and manufacturing silicon photovoltaic products for solar system integrators, project developers, and large commercial and utility customers across the United States, Europe, and other international markets. The company offers crystalline solar modules compatible with tracking systems, along with a range of related services including preliminary system design, energy yield optimization, and cost guidance. Additionally, Solaria provides technical specifications, installation support, troubleshooting, and after-sale services. Founded in 1993 and originally known as Lightchip, Inc., the company rebranded to Solaria Corporation in May 2006. Headquartered in Oakland, California, Solaria also operates offices in Germany, with further locations in India and China, enhancing its global presence in the solar industry.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

NanoSteel is an advanced materials company focused on the design and commercialization of patented steels with superior mechanical properties derived from their nano-scale microstructure. It specializes in proprietary alloys intended for automotive lightweight applications, developing multiple generations of ferrous materials innovations, including metallic coatings and additive manufacturing powders. With over 300 patents filed and granted globally, NanoSteel's nanostructured steel designs deliver next-generation performance across various industrial sectors, including oil and gas, mining, cement, concrete, and power. Its advanced high strength steel (AHSS) sheet material is particularly significant, as it aims to transform steel usage in the automotive industry by enabling manufacturers to produce new, lightweight vehicles that comply with stringent fuel economy regulations while avoiding costly production processes.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of solid tumors, particularly through adoptive TCR-T cell therapy. Utilizing a unique gene expression and control technology, the company aims to engineer cell therapies that specifically target neoantigens resulting from genomic mutations in cancer cells. This approach is designed to enhance the precision and efficacy of cancer treatments by modulating gene expression directly at the tumor site. Currently, Alaunos is evaluating its technology in Phase 2 clinical studies, including the use of the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. The company is also actively pursuing new investigational drug applications for additional targets using its advanced therapeutic platforms.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

PsiloQuest develops and commercializes CMP polishing pads for the semiconductor industry.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.

Catalytic Solutions manufactures and distributes emissions control systems and catalytic products for commercial and industrial applications. It manufactures nanostructured catalysts at its main facility in Oxnard, California. The company’s products are most commonly applied to automobile, diesel engine, and energy markets. Catalytic Solutions has manufacturing facilities in Oxnard, California; Reno, Nevada; Thornhill, Canada; and Malmo, Sweden. Catalytic Solutions, Inc. operates as a subsidiary of Clean Diesel Technologies Inc.